Study to Treat Major Depressive Disorder With a New Medication
Status:
Completed
Trial end date:
2019-08-30
Target enrollment:
Participant gender:
Summary
This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a
novel treatment target for mood disorders through the administration of the KCNQ-selective
channel opener ezogabine (Potiga, GlaxoSmithKline; FDA-approved for the treatment of seizure
disorders).
Phase:
Phase 2
Details
Lead Sponsor:
James Murrough
Collaborators:
Baylor College of Medicine National Institute of Mental Health (NIMH)